Canada - English - Health Canada

angita pharma inc. - duloxetine (duloxetine hydrochloride) - capsule (delayed release) - 30mg - duloxetine (duloxetine hydrochloride) 30mg - selective serotonin and norepinephrine-reuptake inhibitors

Canada - English - Health Canada

angita pharma inc. - duloxetine (duloxetine hydrochloride) - capsule (delayed release) - 60mg - duloxetine (duloxetine hydrochloride) 60mg - selective serotonin and norepinephrine-reuptake inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

3m australia pty ltd - 31783 - crown/bridge, temporary, polymer based - used for short term, temporary restoration during dental treatment

European Union - English - EMA (European Medicines Agency)

warner chilcott  deutschland gmbh - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - livensa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.

European Union - English - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drugs used in diabetes - diabetes mellitus where treatment with insulin is required. insulin human winthrop rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.

European Union - English - EMA (European Medicines Agency)

bayer ag - riociguat - hypertension, pulmonary - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah) adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

European Union - English - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency).this preparation does not contain von willebrand factor and is therefore not indicated in von willebrand's disease.